BioLineRX Ltd. · TASE:BLRX
BioLineRX — Investor Presentation (July 2016)
35 slides from BioLineRX's investor presentation, July 2016

Slide 1: Company Presentation
Company Presentation July 2016

Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains "forward-looking statements." These statements include words like "may," "expects," "believes," “plans,” “scheduled," and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and u

Slide 3: BioLineRx Snapshot
BioLineRx Snapshot • Drug development company focused on oncology & immunology – Founded in 2003 by Teva and other key players in Israeli Life Sciences industry • Bridge “development gap” for Israeli assets – Leverage carefully selected early-stage technology • Lead program is BL-8040 oncology platf

Slide 4: Main Pipeline Assets
Main Pipeline Assets PROJECT INDICATION PRE-CLINICAL PHASE | PHASE II PHASE Ill REGULATORY APPROVAL PARTNERS ir AML Consolidation AML. ‘Stem cell mobilization hMDS/AA Pancreatic cancer Collaboration with Merck for combination study with KEYTRUDA® Celiac disease and gluten sensitivity Type 1 diabetes

Slide 5: Selected Programs
SELECTED PROGRAMS 5

Slide 6: BL-8040: Best-in-Class CXCR4 Antagonist
BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF MULTIPLE CANCER AND HEMATOLOGICAL INDICATIONS 6

Slide 7: BL-8040 Highlights
BL-8040 Highlights • Platform Molecule: Multiple cancer and hematological indications • Received Orphan Designation from FDA for AML & SCM • Mode of Action: Inhibits CXCR4 (a cell surface protein) – CXCR4 overexpressed in >70% of tumors; correlates with severity; well validated – Increases sensitivi

Slide 8: BL-8040 is Best-in-Class vs. Competitors
BL-8040 is Best-in-Class vs. Competitors BMS-936564 BL-8040 Mozobil (MDX1338) Affinity for CXCR4 1-2 nM 84 nM 5nM Inhibition Inverse agonist Antagonist (partial agonist) Antagonist Extracellular domains in the Trans-membrane regions in the Extracellular domains in the CXCR4 Binding site CXCR4 recept

Slide 9: Other Evidence of BL-8040's Superior Anti-Cancer Effect
Other Evidence of BL-8040’s Superior Anti-Cancer Effect BL-8040 (formerly BKT140) inhibits proliferation of Ramos cells compared with Mozobil (AMD3100) and BMS-936564 (MDX-1338) * Study was conducted by scientists from BMS * Kuhne MR, Clinical Cancer Research, 2012 9

Slide 10: BL-8040 Clinical Program
ONGOING PLANNED BL-8040 Clinical Program COMPLETED Pre-Clinical Phase I Phase II Phase III PROTOCOL INDICATION ACUTE MYELOID LEUKEMIA (AML) BL-8040.01 R/R AML Ph2a - Completed BL-8040.04 AML Consolidation (BLAST) Ph2b - Ongoing BL-8040.05 AML FLT3-ITD Ph2a – Planned to initiate H2/2016 IMMUNOTHERAPY

Slide 11: Phase 2a Study in r/r AML Patients Completed
Phase 2a Study in r/r AML Patients Completed • Study Design - Dose escalation phase - Expansion phase: expand safe, efficacious dose group • Multi-center study with 6 sites in US and 4 sites in Israel – US sites include MD Anderson, Sloan Kettering, Mayo Clinic, Johns Hopkins, Washington University

Slide 12: Topline results from Phase 2a Study in r/r AML
Topline results from Phase 2a Study in r/r AML • No major adverse events • Remission rate (CR + CRi) was 38% at doses of 1 mg/kg and higher (n=39) • Triple effect on leukemic cells – Robust leukemic blast mobilization was observed – BL-8040 monotherapy showed direct apoptotic effect on leukemia cell

Slide 13: Successful Results Based on Historical Data
Successful Results Based on Historical Data Best reference for Cytarabine-based chemo regimen is VALOR study* – VALOR study included ~700 patients (~350 on high-dose Cytarabine), topline results reported in 2015 BioLineRx’s Phase 2a VALOR Study Patients 1st & 2nd relapse and refractory 1st relapse &

Slide 14: Stem Cell Mobilization for Transplantation
Stem Cell Mobilization for Transplantation • G-CSF is current standard for stem cell mobilization – 4-6 daily injections of G-CSF, plus 1-4 apheresis sessions required – G-CSF is associated with bone pain and other side effects – G-CSF is not approved for allogeneic transplantation • No agents are a

Slide 15: BL-8040 Potential in Cancer Immunotherapy
BL-8040 Potential in Cancer Immunotherapy • Immunostimulant - BL-8040 is a powerful mobilizer of immune cells from the bone marrow and lymph nodes (T-cells, B-cells, immature Dendritic-cells and NK-cells) • Potentiator - BL-8040 increases infiltration of immune cells into tumors (exhibiting a synerg

Slide 16: BL-8040 Increases Amount of Immune Cells by Mobilization
BL-8040 Increases Amount of Immune Cells by Mobilization Results from Phase 1 trial • Healthy volunteers were treated with BL-8040 or placebo (control) • Single administration of BL-8040 (1 mg/kg) triggered substantial increase in T-cells, B-cells , NK-cells and Dendritic-cells in the blood • Long r

Slide 17: BL-8040 Increases Infiltration of Immune Cells into Tumors
BL-8040 Increases Infiltration of Immune Cells into Tumors Results from Mice Model • Model: Orthotropic syngeneic tumors in pancreas of C57BL/6 male mice • Treatment with BL-8040 for 10 consecutive days, starting PD1 Ab on d3 (-/+) Treatment with BL-8040 induces accumulation of CD3+ T-cells in PDA t

Slide 18: BL-8040 Increases T-Cell Infiltration into Tumors
BL-8040 Increases T-Cell Infiltration into Tumors FACS analysis confirmed enrichment of immune cells within the tumor * Tumor sections were enzymatically digested and single cell suspension were analyzed by FACS ** Values in the table represent absolute cell count 18

Slide 19: BL-8040 promotes an Immuno-permissive Tumor Microenvironment
BL-8040 promotes an Immuno-permissive Tumor Microrenvironment – SDF-1 expression is an independent predictor of poor survival in cancer patients – CXCR4-SDF-1 axis is key pathway mediating attraction of immunosuppressive cells (MDSCs, Tregs, pDCs) to the tumor environment, preventing local T-cell ac

Slide 20: Immunotherapy Collaboration with Merck for Phase 2a Pancreatic Cancer Study
Highlights of Immunotherapy Collaboration with Merck for Phase 2a Study in Pancreatic Cancer • Study highlights: – Combination of BL-8040 with Merck’s anti-PD-1 immune checkpoint inhibitor Pembrolizumab (Keytruda) – Patients with metastatic pancreatic adenocarcinoma – Open-label, multicenter, single

Slide 21: BL-8040 Summary
BL-8040 Summary • CXCR4 is a validated target • BL-8040 has demonstrated signs of efficacy in multiple clinical studies • BL-8040’s MOU has been clinically validated • BL-8040 is a platform for a wide range of oncology and hematology indications – Including immuno-oncology collaboration with Merck f

Slide 22: BL-7010: Novel Gliadin Binding Polymer for Celiac Disease
BL-7010: NOVEL GLIADIN BINDING POLYMER FOR CELIAC DISEASE 22

Slide 23: BL-7010: Polymeric Binder for Celiac Disease & Gluten Sensitivity
BL-7010: Polymeric Binder for Celiac Disease & Gluten Sensitivity • Indication: Celiac disease and gluten sensitivity • Mode of Action: Non-absorbable polymer with high affinity to gliadins (immunogenic peptides contained in gluten) • Status: Phase 1/2 completed; preparations for efficacy study and

Slide 24: Celiac/Gluten Sensitivity – Large Unmet Medical Need
Celiac/Gluten Sensitivity – Large Unmet Medical Need • 1% of world’s population suffers from celiac disease – Number underestimated due to lack of awareness/diagnostic tools • Market projected to reach $8 billion by 2019 • No current pharmacological agents approved for celiac – Only treatment option

Slide 25: BL-7010 Prevents Formation of Gliadin's Immunogenic Peptides
BL-7010 Prevents Formation of Gliadin’s Immunogenic Peptides Gluten Gluten BL-7010 Copolymer of sodium styrene sulfonate (SS) and 2-hydroxyethyl methacrylate (HEMA) Gliadin Enterocytes BL-7010 demonstrates distinguished specificity towards gliadin Small intestinal damage with loss of absorptive vill

Slide 26: BL-7010 Clinical Program Overview
BL-7010 Clinical Program Overview • Phase 1/2 study in celiac patients completed – Single and repeated administrations up to 14 days, 3 times per day – Positive top-line results from study • Safe and well tolerated; no serious or dose-limiting side effects • Optimal dose identified: 1 gram x 3 per d

Slide 27: BL-7010 Summary
BL-7010 Summary • Significant unmet medical need • BL-7010 has unique and simple MOA • Successful Phase 1/2 pilot study – Well tolerated, no systemic exposure • BL-7010 recently classified as Class 2b medical device in Europe • Next efficacy study for gluten sensitivity expected to begin in 2016 27

Slide 28: BL-5010: Novel Formulation and Applicator for Skin Lesion Removal
BL-5010: A NOVEL FORMULATION AND APPLICATOR FOR NON-SURGICAL REMOVAL OF SKIN LESIONS (TOPICAL USE) 28

Slide 29: BL-5010 Highlights
BL-5010 Highlights • Novel formulation/applicator for non-surgical removal of skin lesions • Status: CE mark registration process for OTC indications • Product Highlights: – Medical device classification in EU – Outstanding clinical data • ~97% removal rate; 94% good/excellent cosmetic results – Sta

Slide 30: BL-5010 Roadmap
BL-5010 Roadmap • Partnered with Omega Pharma (now Perrigo) in December 2014 – Licensed rights for OTC indications in Europe, Australia and other territories – Omega/Perrigo obligated to bring two OTC products to market – Completed applicator development and manufacturing process – Selected relevant

Slide 31: Corporate
CORPORATE 31

Slide 32: Strategic Collaboration with Novartis
Strategic Collaboration with Novartis • Novartis selected BioLineRx as its leading partner for identification and early development of Israeli-sourced drug candidates – Exclusive first look at all Israeli-based projects scouted by BioLineRx – Co-develop selected projects through clinical proof-of-co

Slide 33: Financial and Corporate Summary
Financial and Corporate Summary Cash position • $45 million as of March 31, 2016 • Funds operational capital through end of 2018 Capital structure • Traded on NASDAQ and TASE (Symbol: BLRX) • 56 million shares outstanding; 65 million fully diluted • US shareholders represent ~70% of investor base, i

Slide 34: Major Development Milestones – 2016 and 2017
Major Development Milestones – 2016 and 2017 BL-8040 (Pancreatic Cancer) IO agmt with Merck √ BL-8040 (AML) phase 2 completion √ BL-7010 regulatory pathway determination √ BL-8040 (SC Mobilization) phase 2 initiation √ BL-5010 (Skin Lesions) CE Mark approval √ 2016 BL-8040 (Pancreatic Cancer) phase

Slide 35: Benhto Beduideto Patner
Benhto Beduideto Patner BIOLINEM>< 35
Source: Internet Archive copy of biolinerx.com
More decks from BioLineRX Ltd.
Investor Presentation (July 2026)39 slides · July 2026
Q1 2026 Earnings Presentation28 slides · May 27, 2026
Technical Presentation (December 2020)14 slides · Dec 16, 2020
Technical Presentation (December 2020)49 slides · Dec 16, 2020
Investor Presentation (February 2019)31 slides · Feb 4, 2019
Investor Presentation (October 2018)30 slides · Oct 1, 2018